Welcome to our dedicated page for AEMETIS SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AEMETIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AEMETIS's regulatory disclosures and financial reporting.
Aemetis Executive Vice President Sanjeev Gupta received a stock option grant covering 200,000 shares of Common Stock. The option has an exercise price of $2.64 per share, was granted on March 19, 2026, and expires on March 19, 2036. This is a compensation-related award rather than an open-market purchase. Following this grant, Gupta holds options on 1,385,000 shares as reported. According to the vesting terms, one‑twelfth of the option shares vest every three months from the grant date.
ROCKETT JAMES MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Aemetis, Inc. executive vice president and general counsel James Michael Rockett received a grant of stock options, giving him the right to buy 200,000 shares of common stock at $2.64 per share. Following this award, he holds options covering 700,000 shares in total.
The options begin vesting over time. According to the terms, 1/12 of the option shares vest every three months from the grant date of this award, creating a four-year vesting schedule that ties the value of the grant to continued service and the company’s longer-term performance.
BLOCK JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Aemetis, Inc. director John R. Block received a grant of 10,000 shares of Common Stock at $2.64 per share. The award was issued as compensation for his service on the Board of Directors under the Aemetis, Inc. Amended and Restated 2019 Stock Plan. Following this grant, he holds 56,330 shares of Aemetis Common Stock directly.
Aemetis, Inc. Executive Vice President Andrew B. Foster received a grant of stock options, acquiring options to buy 200,000 shares of common stock at $2.64 per share. These options were granted on March 19, 2026 and expire on March 19, 2036.
The options vest over time, with 1/12 of the option shares vesting every three months from the grant date, creating a four-year vesting schedule. Following this award, Foster holds options covering 1,185,834 shares in total, reflecting a compensation-related equity incentive rather than an open-market purchase.
MCAFEE ERIC A reported acquisition or exercise transactions in this Form 4 filing.
Aemetis, Inc. director and Chief Executive Officer Eric A. McAfee received a grant of 300,000 shares of Common Stock at $2.64 per share as a compensation award. The grant was made under the Aemetis, Inc. Amended and Restated 2019 Stock Plan.
After this grant, McAfee is reported as beneficially owning 3,917,316 Common shares, including 1,135,768 shares held directly and 2,781,548 shares held by McAfee Capital LLC. This is a stock award, not an open-market purchase or sale.
Aemetis, Inc. has approved the engagement of KPMG LLP as its independent registered public accounting firm starting with the quarter ending March 31, 2026 and the fiscal year ending December 31, 2026, subject to an engagement letter. The Audit Committee also dismissed RSM US LLP as auditor effective after completion of the December 31, 2025 audit and related non-audit services, ending a relationship that began in 2012. RSM’s reports on the 2024 and 2025 financial statements contained no adverse or qualified opinions, but each included an explanatory paragraph about Aemetis’ ability to continue as a going concern. The company reports no disagreements with RSM and notes previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2024, which were discussed with RSM and about which KPMG may inquire.
Aemetis, Inc. filed its annual report describing a diversified renewable fuels business spanning California ethanol and dairy renewable natural gas (RNG) plus India biodiesel. The company reported a 2025 net loss of $77.0 million, narrowing from $87.5 million in 2024, and an accumulated deficit of $639.9 million as of December 31, 2025.
Keyes ethanol volumes declined to 57 million gallons sold in 2025 from 61 million, while RNG gas sold rose to 399 thousand MMBtu from 302 thousand, and LCFS credits sold increased to 83 thousand. India biodiesel volumes fell sharply to 21 thousand metric tons from 74 thousand. Aemetis highlights large capital projects in sustainable aviation fuel, renewable diesel, and carbon capture, but also discloses heavy leverage, including about $247.9 million owed under Third Eye Capital notes due on demand and $46.2 million of 2025 interest expense.
Aemetis, Inc. reported 2025 results showing strong growth in its dairy renewable natural gas platform but continued overall losses and a weaker top line. Full-year revenues were $197.6 million plus $10.4 million of production tax credits, down from $267.6 million of revenue in 2024. Net loss narrowed to $77.0 million from $87.5 million, helped by cost reductions and tax credit sales.
The dairy RNG segment produced about 405,000 MMBtu in 2025 and increased fourth-quarter production by 61% year over year, generating $9.6 million of gross profit versus $5.4 million in 2024. The California ethanol plant delivered $158.3 million of 2025 revenue and credits, while India biodiesel revenue fell to $29.7 million amid tender delays.
Fourth-quarter 2025 revenue and production tax credits totaled $53.7 million, up from $47.0 million a year earlier, and gross profit improved to $7.7 million from a $2.0 million gross loss. Cash increased to $4.9 million at year-end 2025, but Aemetis carried a stockholders’ deficit of $306.8 million and current liabilities of $371.3 million against total assets of $259.8 million.
Aemetis, Inc. amended its Certificate of Incorporation to increase authorized capital stock to 205,000,000 shares, including a rise in authorized common stock from 80,000,000 to 140,000,000 shares, following stockholder approval at a special meeting.
Stockholders did not approve a reduction in authorized preferred stock from 65,000,000 to 5,000,000 shares, but did approve a discretionary adjournment proposal. Aemetis also updated the official description of its capital stock and filed a legal opinion covering the legality of up to $210,000,000 of common stock that may be sold from time to time under its existing at‑the‑market offering program.
Aemetis, Inc. reported that its subsidiary Aemetis Biogas LLC entered into an Eleventh Waiver and Amendment to its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital Corporation. The amendment extends the deadline to redeem all outstanding Series A Preferred Units from December 31, 2025 to April 30, 2026 and sets the aggregate redemption price at $114.7 million, which reflects prior payments and a $2 million fee for this amendment. If the units are not redeemed by the new date, Aemetis Biogas LLC would instead enter into a credit agreement with Protair-X and Third Eye Capital, effective May 1, 2026, maturing May 1, 2027, with interest at the greater of 16.0% or the prime rate plus 10.0%, guaranteed by Aemetis, Inc. and several subsidiaries and secured by their assets.